Galaxy Biomedical Investment Co.,Ltd. Posted 160 Million Yuan Net Loss in First Three Quarters of 2021

Galaxy Biomedical Investment Co.,Ltd. (北海银河生物产业投资股份有限公司) (000806.SZ) reported a net loss of 160 million yuan in the first three quarters of 2021, reversing a net profit of 38 million yuan for the same period in the previous year.

Meanwhile, the company posted 789.8 million yuan in revenue, down 1.5% year-on-year.

At the end of the reporting period, it had 1.8 billion yuan in total assets and 1.9 billion yuan in total liabilities, with a liability-to-asset ratio of 104.7%.

This article was automatically produced by Caixin Automation on Nov. 3, 2021.

Download our app to receive breaking news alerts and read the news on the go.

Follow the Chinese markets in real time with Caixin Global’s new stock database.